We investigated a possible influence of 2-bromo-alpha-ergocryptine (bromocriptine, CB 154) on the human foetus. The chromosome patterns of the children born to mothers treated with bromocriptine before conception and in early pregnancy were examined. In 19 children no numerical or structural chromosomal anomalies which might be ascribed to the use of bromocriptine could be demonstrated.